{"nctId":"NCT00223080","briefTitle":"HIV Vaccine Trial in Thai Adults","startDateStruct":{"date":"2003-10"},"conditions":["HIV Infection"],"count":16402,"armGroups":[{"label":"Vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ALVAC-HIV vCP1521 + AIDSVAX"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: ALVAC Placebo + AIDSVAX Placebo"]}],"interventions":[{"name":"ALVAC-HIV vCP1521 + AIDSVAX","otherNames":["ALVAC-HIV (vCP1521) >106 CCID50 per 1 mL dose","AIDSVAXÂ® B/E","Bivalent HIV gp120 vaccine subtype B (MN), and E (A244)"]},{"name":"ALVAC Placebo + AIDSVAX Placebo","otherNames":["ALVAC carrier lyophilized product without virus","Aluminum hydroxide adjuvant"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Possession of the 13-digit Thai National ID card\n* 18-30 years of age (inclusive), male or female\n* For women, a negative urine pregnancy test on the day of enrollment, as well as assurance that adequate birth control measures would be applied during the course of the injections and the 3 months after the last injection.\n* Absence of systemic disease or immunodeficiency as determined by medical history and directed physical examination.\n* Negative serology for HIV-1 infection within 45 days prior to enrollment.\n* Availability and commitment for 3.5 years of participation.\n* Able to understand the study (shown by receiving a passing score on the Test of Understanding administered under the screening protocol) and gave written informed consent.\n* Enrollment in and referral from screening protocol, RV148\n\nExclusion Criteria:\n\n* Previous participation in any HIV vaccine trial (unless the volunteer could provide documentation that he/she received placebo).\n* Active tuberculosis, other systemic disease process, or immunodeficiency as detected by medical history and directed physical examination that would, in the opinion of the investigator, impede compliance with study requirements or complicate the interpretation of adverse events.\n* Any significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study or might interfere with the volunteer's ability to successfully complete the study.\n* Occupational or other responsibilities that would prevent completion of 3.5 years of participation in the study.\n* History of anaphylaxis or other serious adverse reactions to vaccines, or allergies or reactions likely to be exacerbated by any component of the vaccine or placebo, including egg products and neomycin.\n* Women breast-feeding or pregnant (positive pregnancy test) or planning to become pregnant during the 9-month window between study enrollment and 3-months after the last vaccination visit.\n* Study site employees who were involved in the protocol and may have had direct access to trial-related data.\n* Chronic use of therapies which may modify immune response, such as IV immune globulin and systemic corticosteroids (in doses of \\> 20 mg prednisone equivalent for periods exceeding 10 days), and use of experimental drugs or vaccines.\n* Receipt of a non-HIV vaccine or immune globulins within 14 days.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"30 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population","description":"HIV-1 infection rate. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null},{"groupId":"OG001","value":"0.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null},{"groupId":"OG001","value":"0.96","spread":null}]}]}]},{"type":"PRIMARY","title":"Vaccine Efficacy as Determined by Acquisition of Infection in the Per-protocol Population","description":"Cumulative Number of HIV Infections. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":null},{"groupId":"OG001","value":"0.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":null},{"groupId":"OG001","value":"0.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in CD4 T Cell Count in Volunteers Who Developed HIV Infection During the Trial for MITT Population","description":"Two CD4 cell counts were obtained (at the verification blood draw and the notification blood draw) and through the remainder of the follow-up period. Results were compared in vaccine and placebo recipients who became HIV-infected during the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"565.4","spread":"43.5"},{"groupId":"OG001","value":"566.7","spread":"26.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"539.6","spread":"37.1"},{"groupId":"OG001","value":"570.6","spread":"29.2"}]}]}]},{"type":"PRIMARY","title":"Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the MITT Population","description":"Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.379","spread":"0.127"},{"groupId":"OG001","value":"4.187","spread":"0.101"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.229","spread":"0.130"},{"groupId":"OG001","value":"4.235","spread":"0.095"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.274","spread":"0.125"},{"groupId":"OG001","value":"4.167","spread":"0.104"}]}]}]},{"type":"PRIMARY","title":"Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the Per Protocol Population","description":"Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.307","spread":"0.154"},{"groupId":"OG001","value":"4.153","spread":"0.136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.128","spread":"0.161"},{"groupId":"OG001","value":"4.276","spread":"0.118"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.280","spread":"0.152"},{"groupId":"OG001","value":"4.143","spread":"0.143"}]}]}]},{"type":"SECONDARY","title":"Safety Assessment (SAE's and AEs)","description":"The intent-to-treat population is used for analysis of AEs and treatment emergent events are reported. Participant AE rates for all AEs, SAEs and treatment-related AEs are summarized","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1277","spread":null},{"groupId":"OG001","value":"1336","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"816","spread":null},{"groupId":"OG001","value":"860","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"614","spread":null},{"groupId":"OG001","value":"597","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"599","spread":null},{"groupId":"OG001","value":"630","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5627","spread":null},{"groupId":"OG001","value":"5685","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in HIV Risk Behaviors Associated With Participation in the Vaccine Trial (MITT)","description":"Self Report of Risk Behavior Status by Treatment and Time. Specifically, this is the responses to the question \"Do you think that your everyday behavior puts you at risk for HIV infection?\" Modified intent to treat population (MITT)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"702","spread":null},{"groupId":"OG001","value":"763","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6223","spread":null},{"groupId":"OG001","value":"6130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"473","spread":null},{"groupId":"OG001","value":"502","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1175,"n":8197},"commonTop":["Pain/Tenderness","Fatigue","Arm Movement Limitation","Myalgia","Pain/Tenderness"]}}}